SelectedAbstractsASCO2010.pptVIP

Selected Abstractsfirst lineASCO 2010 Metastatic NSCLC Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. P. A. Janne 一線標靶治療 Phase III study (TRIBUTE) ECP was associated with improved RR, PFS, and OS compared to CP but only in never-smokers. CALGB 30406 prospectively evaluated E and ECP in never/light former smokers with chemotherapy-na?ve advanced lung adenoca and evaluated the impact of EGFR mutations on outcome. CALGB 30406 CALGB 30406 21 days/cycle X 6 cycles Erlotinib 182 pts Primary endpoint: PFS CALGB 30406 CALGB 30406 Erlotinib單藥治療或與卡鉑+紫杉醇聯合治療6個週期後序貫Erlotinib方案的療效相近，但前者毒性更小。 在兩種方案中，表皮生長因子受體（EGFR）突變者均最有可能獲益。 Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) J. Jassem CP 751,871 Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer Primary endpoint: OS Q3 weeks X 6 cycles SAE in the PCF arm dehydration, hyperglycemia, and hemoptysis Potential relationship with early death (within 42 days of randomization) of a series of clinical and laboratory parameters was investigated Low pre-treatment BMI (p = 0.003) and creatinine clearance (p = 0.1) were predictive of early death for patients receiving figitumumab. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer PFC/PC survival HR estimates favored PC in pts with low baseline IGF-1 (minimum p = 0.006 for IGF1 120 ng/mL; HR 1.6) and PCF in those with high baseline IGF-1 (minimum p = 0.13 for IGF1 145 ng/mL; HR = 0.62). Randomized, open label, phase III trial of figitumumab in combination with p